Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Spyre Therapeutics(US:SYRE) Globenewswire·2026-01-12 13:00“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2 SKYWAY basket trial enrollment on track across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA); All readouts expected in 4Q 2026 Kate Tansey Chevlen appointed Chief Commercial Officer (CCO) Stro ...